Navigation Links
Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
Date:12/6/2012

BLUE BELL, Pa., Dec. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robust vaccine-specific antibody responses in all vaccinated subjects evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses are strong signals of the DNA vaccine's potential to treat the disease.

The data was presented today at an international conference, DNA Vaccines 2012, in San Diego, Ca, by Dr. Christian H. Ottensmeier, MD, PhD, the trial's principal investigator and Professor of Experimental Cancer Research at the University of Southampton, UK. These interim results, from eight patients, are part of a phase II trial that will enroll 31 patients in its chronic myelogenous leukemia (CML) arm. To date, 14 CML patients have been enrolled while another 13 unvaccinated CML patients have been enrolled to serve as a control group. The vaccine has been shown to be safe overall and well-tolerated in the trial subjects. A detailed analysis of T cell immune responses as well as the impact of the vaccination on the molecular marker, BCR-ABL, which is a specific chromosomal abnormality that is associated with chronic myelogenous leukemia (CML) disease, will be performed.

As a result of the favorable safety and immunogenicity profiles observed in the CML vaccinated group, the trial is now open to enroll the acute myeloid leukemia (AML) clinical trial arm, with a total target of 37 subjects in each of the vaccinated and control groups.

This open-label, multi-center phase II clinical trial is evaluating a DNA vaccine-based immune therapy to treat these two types of leukemia. The DNA vaccine, developed by the University of Southampton, is delivered using Inovio's proprietary electroporatio
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
2. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
5. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... generation biofuels are a viable solution to the dilemma of ... is very cheap, this is affecting the biofuels market in ... could be in comparison to natural gas. This, in ... for renewable energy developers to get the economics to work ... certain companies have shifted their focused within renewable energy. ...
(Date:7/29/2014)... , July 29, 2014 ... Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery ... - Global Forecasts & Trends to 2018", published by ... restraints in geographies such as North America ... Asia , and the Rest of the World ...
(Date:7/29/2014)... WARRINGTON, Pa. , July 29, 2014 /PRNewswire/ ... company dedicated to advancing a new standard of ... financial results on August 5, 2014 before the ... The Company will host a live teleconference ... day. During the conference call, Discovery Labs, management ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today ... Inc., to provide access to Nanosyn,s microfluidics screening ... platform for novel small molecule therapeutics. ... to work with FORMA Therapeutics to explore key ... homeostasis. FORMA Therapeutics, decision to work with us ...
Breaking Biology Technology:Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2
... Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... today that,Anthony DiTonno, President and Chief Executive Officer, ... 10th Annual Healthcare Conference in New,York City on ... Ghiglieri,Chief Financial Officer, will also be available to ...
... Company Registered in Switzerland, Will Move its Headquarter ... Various Issues Related to Neovascularisation, - Gene Signal is Working ... Now in Phase III Trials, - Gene Signal Will Present ... the American Academy of Ophtalmologist in Atlanta, USA, the ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today ... Confab on Tuesday, November,11th at 9:40 a.m. ET., ... be accessed under,"Calendar of Events" in the Idenix Investor ... minutes before the,event to ensure a timely connection. The ...
Cached Biology Technology:NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 3Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 2Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 3
(Date:7/29/2014)... , July 29, 2014 Research and ... SaaS-based Business Intelligence (BI) Market 2014-2018" report to ... The term BI refers to applications ... to, or analyzing information about a company,s operations. BI ... affecting their business; for example, metrics on sales, production, ...
(Date:7/29/2014)... But on the remote UK overseas territory of Ascension ... is undergoing something of a renaissance. , Writing in ... the University of Exeter and Ascension Island Government Conservation ... at the remote South Atlantic outpost has increased by ... the 1970s. As many as 24,000 nests are now ...
(Date:7/29/2014)... University of Maryland Schools of Dentistry (UM SOD) ... they have received a five-year $10.7 million grant ... Infectious Diseases (NIAID) of the National Institutes of ... of sexually-transmitted diseases (STDs). The grant, which renews ... represents a new direction for the research by ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4
... Researchers at Rensselaer Polytechnic Institute have secured ... virtual reality simulator for next-generation "scarless" endoscopic surgery. ... National Institutes of Health (NIH), seeks to accelerate ... or NOTES. This emerging surgical technique shows promise ...
... those battery-pack organelles that fuel the energy of almost ... Whether in a dish or a living organism, the ... Because calcium levels link to many essential biological processesnot ... have been working for half a century to identify ...
... Scientists and educators alike have long known that cramming ... their latest findings, researchers at the RIKEN Brain Science ... mice, have elucidated the neurological mechanism explaining why this ... , their results suggest that protein synthesis in the ...
Cached Biology News:Rensselaer researchers secure $2.7 million NIH grant to advance 'scarless' surgery 2Rensselaer researchers secure $2.7 million NIH grant to advance 'scarless' surgery 350-year search for calcium channel ends 250-year search for calcium channel ends 3A better way to remember 2
... Chain MAP1A and MAP1B are microtubule-associated proteins ... components of the cytoskeleton. MAP1A and MAP1B each ... light chain subunits. The protein encoded by this ... and can associate with either MAP1A or MAP1B. ...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Biology Products: